Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662215 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
A Phase 1 study, sponsored by Cytokinetics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT05662215 is a Phase 1 study that was terminated before completion, run by Cytokinetics. The registered enrollment target is 57 participants.
The verdict
NCT05662215, a Phase 1 study, was terminated before completion, sponsored by Cytokinetics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.
Interventions
- DRUG CK-3828136
- DRUG Placebo for CK-3828136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05662215
The ClinicalTrials.gov registry entry for NCT05662215 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CK-3828136 is the first listed.
NCT05662215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05662215 about?
NCT05662215 is a clinical study titled "A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants". 1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.
What is the current status of trial NCT05662215?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-12-06. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05662215?
The interventions under investigation include: CK-3828136 (DRUG), Placebo for CK-3828136 (DRUG).
Who is sponsoring clinical trial NCT05662215?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.